A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs BBT-401 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Bridge Biotherapeutics
- 22 Oct 2019 Planned End Date changed from 15 May 2020 to 15 Dec 2020.
- 22 Oct 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2020.
- 11 Feb 2019 According to a Bridge Biotherapeutics media release, the first cohort is open for enrollment with a targeted completion by the end of the year.